Thibaut Roulon serves as a Senior Investment Director for Life Sciences at Bpifrance since July 2013, where the organization manages over €50 billion and invests in life science companies at various development stages. In addition, Thibaut holds board positions at several innovative companies, including Nouscom, which develops neoantigen cancer vaccines; Depixus, focused on molecular interaction monitoring technology; AlgoTx, specializing in treatments for chemotherapy-induced neuropathies; ImCheck Therapeutics, which aims to activate γ9δ2 T cells through novel immunotherapeutics; Step Pharma, working on a drug candidate for certain malignancies; Advicenne, dedicated to rare kidney disease treatments; and NH TherAguix, developing nanomedicines with radiosensitizing properties. Thibaut previously served as a board observer at GenSight Biologics, engaged in gene therapies for retinal diseases. Academic credentials include a Ph.D. in Molecular Biophysics from Pierre and Marie Curie University and an Engineering degree from CentraleSupélec.
This person is not in the org chart
This person is not in any teams
This person is not in any offices